Dae Yeol Lee

Dae Y. Lee received his doctorate in 2009 from the Rutgers University, Ernest Mario School of Pharmacy (Pharm.D).  He received his J.D. in 2012 from the Maurice A. Deane School of Law at Hofstra University.  In 2017, Mr. Lee was named by The National Trial Lawyers to New York’s Top 40 Under 40 Civil Plaintiff’s Attorneys.

Mr. Lee focuses his practice in the areas of medical device and pharmaceutical product liability litigation.  He has represented the interests of clients in various product liability cases, including, but not limited to Actos, Incretin-based and other diabetes medications, Fresenius GranfuFlo/NaturaLyte dialysate, Da Vinci surgical devices, and power morcellators.  Mr. Lee is currently handling litigation involving the prescription drug Risperdal, in which he represents the interests of bellwether trial plaintiffs and frequently makes court appearances for oral arguments.  He also represents clients injured by fluoroquinolone antibiotics, testosterone supplements, SGLT-2 diabetes medications, and forced air warming devices used during surgical procedures.

Prior to joining Bernstein Liebhard LLP, Mr. Lee represented injured consumers in pharmaceutical litigation at a Manhattan law firm, where he was involved in case development and investigation, as well as all aspects of pre-trial litigation.

Mr. Lee is admitted to the Bars of the State of New York and New Jersey.

Published July 5, 2013 by